NTC, a global leader in pharmaceuticals, has announced the launch of its Imperial product line, a revolutionary range of eye drops developed in collaboration with Silgan Dispensing Systems. The new line incorporates Silgan’s cutting-edge Iridya™ technology, a preservative-free multidose eye dropper designed to enhance patient comfort and treatment outcomes.
A New Standard for Dry Eye Treatment
The Imperial product line sets a new standard in the treatment of dry eye conditions by combining advanced design with patient-centric features. The collaboration between NTC and Silgan Dispensing Systems allows for the commercialization of NTC’s proprietary eye drops, supported by Iridya™ technology. This technology offers patients a preservative-free solution that not only enhances safety but also delivers precise and consistent dosing.
Marcello Selvaggio, NTC’s Global Head of Ophthalmology, emphasized the company’s commitment to patient satisfaction, stating:
“With Iridya™, we’ve elevated our range of dry eye treatments, offering more advanced and patient-focused solutions.” The Imperial line offers a unique solution by blending the best aspects of existing multidose preservative-free devices into one advanced product. Our goal is to ensure maximum patient compliance and satisfaction.”
Innovative Design for Optimal Dosing
The Imperial product line stands out due to its innovative design, which is tailored to the specific needs of dry eye patients. The Iridya™ dropper features exceptional control over the size and consistency of each drop, ensuring precise dosing. Additionally, the elongated tip allows for greater accuracy during application, reducing the margin for error and improving patient comfort.
The ergonomic design further enhances usability, with a low-squeeze force bottle that requires minimal effort, making it ideal for long-term use. This thoughtful design is particularly beneficial for patients who may struggle with traditional eye drop bottles due to dexterity issues or the chronic nature of their condition.
Launch at CPhI Milan
NTC is set to officially introduce the Imperial product line at CPhI Milan, a premier global event in the pharmaceutical industry. This launch will include a detailed presentation of the product’s innovative features and benefits, supported by clinical evidence. NTC will highlight how the Iridya™ technology ensures reliable drop delivery and preserves the integrity of the product without the need for harmful preservatives.
Riccardo Carbucicchio, CEO of NTC, expressed the company’s enthusiasm about this new launch:
“The introduction of the Imperial line marks another milestone in our mission to meet unmet medical needs. Our continuous pursuit of innovation is reflected in this product, which is designed to stay on the patient’s side, enhancing their overall experience with dry eye treatments.”
Partnership with Silgan Dispensing Systems
This collaboration represents a significant partnership between NTC and Silgan Dispensing Systems, a global leader in healthcare dispensing solutions. Eric Demaris, Commercial Director for EMEA at Silgan Dispensing Healthcare, stated:
“We are excited to collaborate with NTC, a renowned leader in ophthalmic care. Through Iridya™ technology, we are confident that this collaboration will deliver improved solutions for dry eye treatment, ensuring accurate dosing and enhanced safety for patients.”
A Commitment to Patient-Centric Innovation
NTC’s Imperial product line reinforces its long-standing commitment to innovation and patient care. By offering advanced products that cater to real-world patient needs, NTC continues to improve compliance and treatment outcomes. The Imperial line exemplifies NTC’s mission to make healthcare solutions that are not only effective but also accessible and user-friendly.
